Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.44 |
| ▸ | IDH1 | O75874 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292405 | 1.00 | NAAA (0.44) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL15873097 | 1.00 | NAAA (0.44) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL7331796 | 0.95 | NAAA (0.43) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL7405405 | 0.95 | IDH1 (0.43) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL7405402 | 0.95 | IDH1 (0.43) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL7501411 | 0.95 | NAAA (0.43) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL10321433 | 0.94 | NAAA (0.46) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL10321430 | 0.94 | NAAA (0.46) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL10321432 | 0.94 | NAAA (0.46) | NAAAIDH1ALDH1A1PPARAFAAH | |
| SCHEMBL2073646 | 0.94 | IDH1 (0.44) | NAAAIDH1ALDH1A1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696331-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20250304717-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025103367-A1 | LIGAND-DRUG CONJUGATE, LINKER FOR CONJUGATION, AND USE THEREOF | 海南先声再明医药股份有限公司 | 2025-05-22 | — | — | WO | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024213128-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 山东先声生物制药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| WO-2024144149-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2024-07-04 | — | — | WO | disclosed |
| EP-4282868-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE DERIVATIVE, AND COMPOSITIONS AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2023217227-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | 先声再明医药有限公司 | 2023-11-16 | — | — | WO | disclosed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| WO-2021011723-A1 | ANTI-OSTEOARTHRITIS HYDANTOIN COMPOUNDS AND RELATED COMPOSITIONS AND METHODS | AVIDENCE THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-2861601-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | NAAA 1328/4885IDH1 4408/4885ALDH1A1 3565/4885 |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | NAAA 2665/4885IDH1 881/4885ALDH1A1 1293/4885 |
| US-20250304717-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | LPXN, CLSPN, SELL | NAAA 3221/4885IDH1 2278/4885ALDH1A1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.